LEADER 01607nam  2200349   450 
001 9910688590203321
005 20230701032349.0
035   $a(CKB)5400000000044877
035   $a(NjHacI)995400000000044877
035   $a(EXLCZ)995400000000044877
100   $a20230701d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMetformin $epharmacology and drug interactions /$fJuber Akhtar [and three others], editor
210  1$aLondon :$cIntechOpen,$d2021.
215   $a1 online resource (154 pages)
311   $a1-83969-607-9 
330   $aType 2 diabetes (T2D), also known as non-insulin-dependent diabetes mellitus (NIDDM), is a condition in which cells fail to respond to insulin properly. As the disease progresses, the body does not produce enough insulin. There are several classes of anti-diabetic medications available, including the oral agent metformin. This medication is recommended as first-line treatment for T2D, except for those patients with severe kidney or liver problems. This book discusses the molecular mechanism, pharmacokinetics, and uses of metformin, as well as presents information on adverse drug reactions, drug interactions, and the potential use of metformin in tuberculosis.
517   $aMetformin 
606   $aMetformin
615  0$aMetformin.
676   $a616.462061
702   $aAkhtar$b Juber
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688590203321
996   $aMetformin$91952071
997   $aUNINA